Expression of p53 and Glutathione S-Transferase-π Relates to Clinical Drug Resistance in Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|57|4|318-323

ISSN： 0030-2414

Source： Oncology, Vol.57, Iss.4, 1999-11, pp. : 318-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Relevance of Altered pRb and p53 Protein Expression in Surgically Treated Non-Small Cell Lung Cancer Patients

By  

Oncology, Vol. 67, Iss. 1, 2004-10 ,pp. : 60-66

Karger

Access to resources Recommend Favorite

Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase-π and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic Chemotherapy

By  

Oncology, Vol. 62, Iss. 4, 2002-07 ,pp. : 305-312

Karger

Access to resources Recommend Favorite

Clinical Characteristics of 274 Non-Small Cell Lung Cancer Patients in China

By  

Oncology Research and Treatment, Vol. 36, Iss. 5, 2013-04 ,pp. : 248-254

Karger

Access to resources Recommend Favorite

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2299-2307

John Wiley & Sons Inc

Access to resources Recommend Favorite

Docetaxel in non-small cell lung cancer

By Souquet Pierre-Jean   Geriniere Laurence  

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 579-590

Future Medicine

Access to resources Recommend Favorite